ARPC4: A Potential Drug Target and Biomarker (G10093)

Target Name: ARPC4

NCBI ID: G10093

ARPC4

ARPC4: A Potential Drug Target and Biomarker

Apoptosis, or programmed cell death, is a natural occurrence in the life cycle of all living organisms. It is a critical process that helps remove damaged or unnecessary cells from the body, ensuring overall health and wellbeing. However, when apoptosis fails to occur properly, it can lead to the development of diseases such as cancer, neurodegenerative disorders, and cardiovascular diseases. One of the key factors that contribute to these diseases is the regulation of apoptosis, and the protein ARPC4 is of particular interest as a drug target and biomarker.

ARPC4: Structure and Function

The ARPC4 protein is a member of the Apo family, which is known for their role in the regulation of apoptosis. The Apo family consists of six structurally similar but functionally distinct proteins: Apo1, Apo2, Apo3, Apo4, Apo5, and Apo6. These proteins share a conserved catalytic core and a common N-terminus, but they differ in their lengths and the specific functions they exhibit.

ARPC4 is a 16-kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and pancreas. It is involved in the regulation of apoptosis and has been shown to play a role in the development and progression of neurodegenerative diseases.

ARPC4 is involved in the regulation of cell apoptosis, which is the process by which cells decide when to die and are removed from the body. During apoptosis, ARPC4 helps to coordinate the release of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, which have been shown to contribute to the development of neurodegenerative diseases.

In addition to its role in apoptosis, ARPC4 has also been shown to play a key role in the regulation of cell survival and proliferation. It has been shown to promote the survival of neurons and to inhibit the formation of neuroblasts, which are cells that give rise to new neurons.

ARPC4 as a Drug Target

The potential use of ARPC4 as a drug target is based on its involvement in the regulation of apoptosis and its ability to promote neurodegenerative diseases. Several studies have shown that blocking ARPC4 can be effective in treating neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the reasons for the potential effectiveness of ARPC4 as a drug target is its ability to interact with several other proteins, including Bcl-2, a protein that has been shown to promote the survival of neurons. By inhibiting Bcl-2, ARPC4 has been shown to reduce the formation of neuroblasts and to promote the apoptosis of neurons, which can be effective in treating neurodegenerative diseases.

Another reason for the potential effectiveness of ARPC4 as a drug target is its ability to modulate the levels of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾, which have been shown to contribute to the development of neurodegenerative diseases. By inhibiting the activity of ARPC4, it has been shown to reduce the levels of these cytokines and to improve the sensitivity of cells to therapeutic treatments.

ARPC4 as a Biomarker

The regulation of apoptosis is a critical process that contributes to the development and progression of many diseases, including neurodegenerative diseases. As such, ARPC4 has been shown to be a potential biomarker for the diagnosis and progression of these diseases.

The ability of ARPC4 to regulate apoptosis and to interact with other proteins makes it an attractive candidate for use as a biomarker for neurodegenerative diseases. Several studies have shown that ARPC4 levels are decreased in the brains of individuals with neurodegenerative diseases, and that these levels are correlated with the severity of the disease.

In addition, the ability of ARPC4 to modulate the levels of pro-inflammatory cytokines makes it an attractive candidate

Protein Name: Actin Related Protein 2/3 Complex Subunit 4

Functions: Actin-binding component of the Arp2/3 complex, a multiprotein complex that mediates actin polymerization upon stimulation by nucleation-promoting factor (NPF) (PubMed:9230079). The Arp2/3 complex mediates the formation of branched actin networks in the cytoplasm, providing the force for cell motility (PubMed:9230079). In addition to its role in the cytoplasmic cytoskeleton, the Arp2/3 complex also promotes actin polymerization in the nucleus, thereby regulating gene transcription and repair of damaged DNA (PubMed:29925947). The Arp2/3 complex promotes homologous recombination (HR) repair in response to DNA damage by promoting nuclear actin polymerization, leading to drive motility of double-strand breaks (DSBs) (PubMed:29925947)

The "ARPC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARPC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets